Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 254

Sort by

Sort Order Select

Journal Articles

Checkpoint inhibitors and thrombosis: what’s up?

Jan Beyer-Westendorf

Blood (2021) 137 (12): 1569–1570.

https://doi.org/10.1182/blood.2020009480

Published: 2021

Journal Articles

Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy

Florian Moik, Wei-Shin Evelyn Chan, Sarah Wiedemann, Christoph Hoeller, Felix Tuchmann, Marie-Bernadette Aretin, Thorsten Fuereder, Sabine Zöchbauer-Müller, Matthias Preusser, Ingrid Pabinger, Cihan Ay

Blood (2021) 137 (12): 1669–1678.

https://doi.org/10.1182/blood.2020007878

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

N. Nora Bennani, MD, Levi D Pederson, Pamela Atherton, Ivana Micallef, MD, Joseph P. Colgan, MD, Gita Thanarajasingam, MD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD, Andrew L. Feldman, MD, Stephen M Ansell, MD

Blood (2019) 134 (Supplement_1): 467.

https://doi.org/10.1182/blood-2019-126194

Published: 2019

Journal Articles

RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade

Simon Heidegger, MD, Alexander Wintges, Florian Stritzke, Katja Steiger, Paul-Albert Koenig, Thomas Engleitner, Julius Clemens Fischer, Vladimir Makarov, Christof Winter, Roland Rad, Marcel R.M. van den Brink, MD PhD, Jürgen Ruland, Florian Bassermann, MD PhD, Timothy Chan, Tobias Haas, MD, Hendrik Poeck, MD

Blood (2019) 134 (Supplement_1): 624.

https://doi.org/10.1182/blood-2019-128724

Published: 2019

Journal Articles

An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma

Chloe B. Steen, MSc, Bogdan A. Luca, PhD, Mohammad Shahrokh Esfahani, Barzin Y. Nabet, PhD, Brian Sworder, MD PhD, Farshad Farshidfar, MD PhD, Kiarash Shamardani, BA, David M. Kurtz, MD PhD, Chih Long Liu, PhD, Ranjana H Advani, MD, Yasodha Natkunam, MD PhD, June Helen Myklebust, PhD, Maximilian Diehn, MD PhD, Andrew Gentles, PhD, Aaron M Newman, PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 655.

https://doi.org/10.1182/blood-2019-129461

Published: 2019

Journal Articles

Mitochondrial Complex II in Intestinal Epithelial Cells Is a Critical Metabolic Checkpoint That Regulates Severity of Gastrointestinal Graft-Versus-Host Disease

Hideaki Fujiwara, Anna V Mathew, Ilya Kovalenko, Pal Anupama, Dan Peltier, Stephanie Kim, Austin Taylor, BA, Katherine Oravecz-Wilson, Yaping Sun, Costas Lyssiotis, Alnawaz Rehemtulla, Subramanian Pennarthur, Pavan Reddy

Blood (2019) 134 (Supplement_1): 584.

https://doi.org/10.1182/blood-2019-126775

Published: 2019

Journal Articles

Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma

Lijie Xing, MD, Liang Lin, PhD, Tengteng Yu, MD PhD, Yuyin Li, PhD, Kenneth Wen, BS, Shih-Feng Cho, MD PhD, Phillip A Hsieh, Krista Kinneer, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 1817.

https://doi.org/10.1182/blood-2019-127163

Published: 2019

Journal Articles

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

Je-Jung Lee, MD PhD, Tan-Huy Chu, Manh-Cuong Vo, Hye-Sung Park, Thangaraj Jaya Lakshmi, Seo-Yeon Ahn, MD, Ga-Young Song, Sung-Hoon Jung, MD, Hyeoung-Joon Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1819.

https://doi.org/10.1182/blood-2019-127964

Published: 2019

Journal Articles

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Christie P.M. Verkleij, MD, Monique C. Minnema, Okke de Weerdt, MD, Patricia W.C. Bosman, MSc, Kristine A. Frerichs, MD, Alexandra J. Croockewit, MD PhD, Saskia K. Klein, MD PhD, Gerard Bos, MD PhD, Tuna Mutis, Wouter J. Plattel, MD, Ellen van der Spek, MD PhD, Annemiek Broyl, MD PhD, Pieter Sonneveld, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Niels W. C. J. Van De Donk, MD PhD

Blood (2019) 134 (Supplement_1): 1879.

https://doi.org/10.1182/blood-2019-124339

Published: 2019

Journal Articles

Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination

John Richards, PhD, Myriam N Bouchlaka, BS,PhD, Robyn J Puro, PhD, Ben J Capoccia, PhD, Ronald R Hiebsch, BS, Michael J Donio, BS, W. Casey Wilson, PhD, Prabir Chakraborty, PhD, Victoria Sung, PhD, Daniel S Pereira, PhD

Blood (2019) 134 (Supplement_1): 1844.

https://doi.org/10.1182/blood-2019-126298

Published: 2019

Journal Articles

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Meng Wang, BS, Iulian Pruteanu, PhD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Lifeng Tian, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Jennifer Brogdon, PhD, Megan Davis, PhD, Vanessa E. Gonzalez, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Michael C. Milone, Edward A. Stadtmauer, MD FACP, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 1909.

https://doi.org/10.1182/blood-2019-122396

Published: 2019

Journal Articles

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Amy Wang, MD MPH, Justin Kline, MD, Wendy Stock, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Peter A. Riedell, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2019) 134 (Supplement_1): 1956.

https://doi.org/10.1182/blood-2019-123887

Published: 2019

Journal Articles

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

Jeong A Park, MD PhD, Hong fen Guo, PhD, Hong Xu, PhD, Nai-Kong V. Cheung, MD PhD

Blood (2019) 134 (Supplement_1): 1959.

https://doi.org/10.1182/blood-2019-131325

Published: 2019

Journal Articles

Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents

R. Alejandro Sica, MD, Michael A Spinner, John S Tamaresis, PhD, Ranjana H Advani, MD, Laura J Johnston, MD, Robert Lowsky, MD, Everett H Meyer, MD PhD, David B Miklos, MD PhD, Lori S Muffly, MD, Andrew R Rezvani, MD, Judith A Shizuru, MD PhD, Wen-Kai Weng, MD PhD, Robert S. Negrin, MD, Sally Arai, MD

Blood (2019) 134 (Supplement_1): 2022.

https://doi.org/10.1182/blood-2019-131532

Published: 2019

Journal Articles

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Jeffrey S. Miller, MD, Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Sajid Mahmood, PhD, Paul Rogers, PhD, Ge Moyar, Bruce R. Blazar, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD, Frank Cichocki, PhD

Blood (2019) 134 (Supplement_1): 1933.

https://doi.org/10.1182/blood-2019-124961

Published: 2019

Journal Articles

Blocking MAPK Activation and Immune Checkpoints Reverse Immune Dysfunction and Reduce Disease in a Mouse Model of LCH

Amel Sengal, BS, Meryl Hahne, Jessica Velasquez, Harshal Abhyankar, MS, Thomas Burke, BS, Walter Olea, Robert Reyes, Brooks Scull, MS, Camille Bigenwald, Catherine M. Bollard, MD, Wendong Yu, Miriam Merad, MD, Kenneth L. McClain, MD PhD, Carl E. Allen, MD PhD, Rikhia Chakraborty, PhD

Blood (2019) 134 (Supplement_1): 3602.

https://doi.org/10.1182/blood-2019-128253

Published: 2019

Journal Articles

Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series

Karthik Gnanapandithan, MD MS, Prakash Kharel, MD, Alyssa Grimshaw, MSLIS, Smith Giri, MBBS

Blood (2019) 134 (Supplement_1): 3606.

https://doi.org/10.1182/blood-2019-132203

Published: 2019

Journal Articles

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Sigrid Dubois, PhD, Jennifer Hsu, RN, Jeffrey Schlom, PhD, James Gulley, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 1558.

https://doi.org/10.1182/blood-2019-128945

Published: 2019

Journal Articles

Safety and Efficacy of Allogeneic Stem Cell Transplantation after PD-1 Blockade for Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Anastasiya V Beynarovich, MD, Kirill Lepik, Nataliia Mikhailova, Elena Kondakova, Yuri Zalaylov, Evgeniya Borzenkova, Elena Babenko, Elena I Darskaya, MD PhD, Ivan S Moiseev, MD PhD, Axel Zander, Boris Afanasyev

Blood (2019) 134 (Supplement_1): 1561.

https://doi.org/10.1182/blood-2019-129076

Published: 2019

Journal Articles

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Rory M Shallis, MD, Jan Philipp Bewersdorf, MD, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Thomas Prebet, MD PhD, Steven D. Gore, MD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 1330.

https://doi.org/10.1182/blood-2019-127422

Published: 2019

NARROW

Checkpoint inhibitors and thrombosis: what’s up?

Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade

An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma

Mitochondrial Complex II in Intestinal Epithelial Cells Is a Critical Metabolic Checkpoint That Regulates Severity of Gastrointestinal Graft-Versus-Host Disease

Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Blocking MAPK Activation and Immune Checkpoints Reverse Immune Dysfunction and Reduce Disease in a Mouse Model of LCH

Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Safety and Efficacy of Allogeneic Stem Cell Transplantation after PD-1 Blockade for Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only